Latest Mesenchymal stem cell Stories
A study on mice suggests that adult stem cells from immune system tissue in the smell-sensing region of the human nose could provide a source of cells to treat brain disorders in which nerve cells are lost or irreparably damaged.
CLEVELAND, June 7, 2011 /PRNewswire-USNewswire/ -- Arteriocyte(TM), a leading clinical stage biotechnology company with offices in Cleveland, Ohio, and Hopkinton, Massachusetts, that develops proprietary stem cell and tissue engineering based therapies, announced today that they have entered into a Cooperative Research and Development Agreement (CRADA) with the United States Army Institute of Surgical Research (USAISR) at Fort Sam Houston, Texas.
HONOLULU, April 19, 2011 /PRNewswire/ -- Tissue Genesis, Inc., an emerging leader in adult stem cell and regenerative medicine, announced today that it has begun clinical trials for peripheral vascular disease (PVD) with adipose (fat) derived adult stem cell-coated vascular grafts at the University of Louisville Hospital.
A type of adult stem cell is now proving itself more versatile for research and therapies thanks to revolutionary 3D experiments.
BOSTON, March 28, 2011 /PRNewswire/ -- For over 15 years now, parents have had the option to save the blood that is found within their baby's umbilical cord immediately following birth. The blood is rich in hematopoietic stem cells (HSC's).
Itâ€™s been shown for the first time that stem cells injected into enlarged hearts reduced hear size, reduced scar tissue, and improved function to injured heart areas, according to this human trial.
A fibroblast is not always just a fibroblast â€“ particularly in the heart.
Researchers have shown for the first time that stem cells injected into enlarged hearts reduced heart size, reduced scar tissue and improved function to injured heart areas.
CARLSBAD, Calif., March.
Stemedica announced today that it has received Institutional Review Board (IRB) approval from the University of California, San Diego (UCSD) to initiate a Stemedica clinical study entitled, "A Phase I/II, Multi-Center, Open-Label Study to Assess the Safety, Tolerability and Preliminary Efficacy of a Single Intravenous Dose of Allogeneic Mesenchymal Bone Marrow Cells to Subjects With Ischemic Stroke". San Diego, CA (PRWEB) February 17, 2011 Stemedica Cell Technologies, Inc., a...
- A trick or prank.